RxDoctor Payments Data

Lana Simmons

Nurse Practitioner · Statesville, NCNPI 1134317241

Payments from drug & device makers

$2,924in general payments, 2019–2025

Across 157 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$486
  • Novo Nordisk$379
  • AstraZeneca$336
  • GSK$247
  • Pfizer$230
  • Lilly USA, LLC$190
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$2,924100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,924 in reported general payments places this provider in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$29,640
Medicare patients
93
Services billed
862

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide47$39,159
OzempicSemaglutide23$36,356
EliquisApixaban31$28,673
MyrbetriqMirabegron17$15,687
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$14,616
Ventolin HfaAlbuterol Sulfate24$1,458
PaxlovidNirmatrelvir/Ritonavir13$1,429
Gabapentin55$1,361
Omeprazole87$1,153
Duloxetine Hcl30$981
Albuterol Sulfate HfaAlbuterol Sulfate37$864
Atorvastatin Calcium107$837
Celecoxib28$706
Amlodipine Besylate74$703
Levothyroxine Sodium68$566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$486$39,15947 claims
Novo NordiskOzempic$379$36,35623 claims
PfizerEliquis, Paxlovid$230$30,10244 claims
Astellas Pharma US IncMyrbetriq$42$15,68717 claims
GSKTrelegy Ellipta$247$14,61622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Statesville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →